Literature DB >> 27878136

Phenotypic convergence of Menkes and Wilson disease.

Boglarka Bansagi1, David Lewis-Smith1, Endre Pal1, Jennifer Duff1, Helen Griffin1, Angela Pyle1, Juliane S Müller1, Gabor Rudas1, Zsuzsanna Aranyi1, Hanns Lochmüller1, Patrick F Chinnery1, Rita Horvath1.   

Abstract

Menkes disease is an X-linked multisystem disorder with epilepsy, kinky hair, and neurodegeneration caused by mutations in the copper transporter ATP7A. Other ATP7A mutations have been linked to juvenile occipital horn syndrome and adult-onset hereditary motor neuropathy.1,2 About 5%-10% of the patients present with "atypical Menkes disease" characterized by longer survival, cerebellar ataxia, and developmental delay.2 The intracellular copper transport is regulated by 2 P type ATPase copper transporters ATP7A and ATP7B. These proteins are expressed in the trans-Golgi network that guides copper to intracellular compartments, and in copper excess, it relocates copper to the plasma membrane to pump it out from the cells.3ATP7B mutations cause Wilson disease with dystonia, ataxia, tremor, and abnormal copper accumulation in the brain, liver, and other organs.4.

Entities:  

Year:  2016        PMID: 27878136      PMCID: PMC5114694          DOI: 10.1212/NXG.0000000000000119

Source DB:  PubMed          Journal:  Neurol Genet        ISSN: 2376-7839


Menkes disease is an X-linked multisystem disorder with epilepsy, kinky hair, and neurodegeneration caused by mutations in the copper transporter ATP7A. Other ATP7A mutations have been linked to juvenile occipital horn syndrome and adult-onset hereditary motor neuropathy.[1,2] About 5%–10% of the patients present with “atypical Menkes disease” characterized by longer survival, cerebellar ataxia, and developmental delay.[2] The intracellular copper transport is regulated by 2 P type ATPase copper transporters ATP7A and ATP7B. These proteins are expressed in the trans-Golgi network that guides copper to intracellular compartments, and in copper excess, it relocates copper to the plasma membrane to pump it out from the cells.[3] ATP7B mutations cause Wilson disease with dystonia, ataxia, tremor, and abnormal copper accumulation in the brain, liver, and other organs.[4] Here, we report an ATP7A mutation, manifesting with an unusual complex phenotype resembling Wilson disease.

Methods.

A 29-year-old man was born to a nonconsanguineous family; his father and paternal uncle suffer from genetically confirmed X-linked Kennedy disease. He achieved normal developmental milestones and manifested with progressive gait ataxia and proximal and distal leg weakness with early teens onset. Four limb spasticity evolved with extrapyramidal movement disorder, and he started using wheelchair at the age of 20. Clinical examination detected normal stature with no skeletal and joint changes and no connective tissue, cardiovascular, or hepatic abnormalities. He had normal vision and no evidence of Kayser-Fleischer rings, but bilateral nystagmus was present. He had severe spasticity and dystonia in all four extremities. Deep tendon reflexes were increased (4+) except for absent ankle jerks; clonus was present; and Babinski sign was positive. Cerebellar symptoms associated include intention tremor, dysmetria, and dysdiadochokinesis, and Romberg test was positive. His gait was spastic-ataxic (figure, A and C). He had dysarthria but preserved cognition and no mental illness. Routine laboratory investigations were normal. Metabolic tests including coeruloplasmin (0.19 g/L) and copper in serum and urine were repeatedly normal. EMG of the left tibial anterior muscle revealed increased insertional activity with fibrillations and larger motor units. Nerve conduction velocities were normal, but amplitudes were reduced in the peroneal and medial nerves, suggesting axonal motor neuropathy. Initial brain MRI at 9 years of age indicated high signal intensity of bilateral globus pallidus on T2-weighed images. Follow-up scan at age 29 years showed mildly increased signal intensity of bilateral globus pallidus on fluid-attenuated inversion recovery (FLAIR) sequences but not on T2-weighed images and mild cerebellar atrophy (figure, B).
Figure

Clinical presentation, neuroimaging, and immunoblotting

(A) Photograph of the patient illustrates spasticity. (B) Neuroimages indicate bilateral abnormal signal intensity in the globus pallidus (T2, fluid-attenuated inversion recovery) and mild cerebellar atrophy (T1). (C) Leading clinical symptoms. (D) Immunoblot analysis detected severely reduced ATP7A protein in the patient's fibroblasts.

Clinical presentation, neuroimaging, and immunoblotting

(A) Photograph of the patient illustrates spasticity. (B) Neuroimages indicate bilateral abnormal signal intensity in the globus pallidus (T2, fluid-attenuated inversion recovery) and mild cerebellar atrophy (T1). (C) Leading clinical symptoms. (D) Immunoblot analysis detected severely reduced ATP7A protein in the patient's fibroblasts. Genetic testing was negative for Kennedy disease and common ataxias. Illumina TruSeq 62 Mb exome capture, sequencing (100 bp paired-end reads, HiSeq 2000; Illumina, San Diego, CA), and alignment (UCSC hg19) was performed in the patient. Potentially deleterious recessive or X-linked variants were identified using QIAGEN Ingenuity Variant Analysis and validated by Sanger sequencing. Immunoblotting was performed using standard protocols.[1]

Results.

The patient carried the hemizygous c.2279A>G, p.(Tyr760Cys) variant in ATP7A. His healthy mother was heterozygous for the sequence change which was absent in her healthy brother. The variant was rare (Exome Aggregation Consortium: 4 in 87,766 heterozygous X chromosomes, no hemizygous), predicted highly deleterious by 5 different prediction tools, and affected a highly conserved residue in the third transmembrane domain of ATP7A. The neighboring p.(Ser761Pro) has been associated with the moderate Menkes phenotype.[2] Immunoblotting confirmed severely reduced ATP7A protein in the patient's fibroblasts compared with the control (figure, D).

Discussion.

We identified the c.2279A>G, p.(Tyr760Cys) ATP7A variant in a patient with complex neurologic signs of spastic tetraparesis, ataxia, dystonia, and axonal motor neuropathy. The mutation segregated with the disease in the family and resulted in reduced ATP7A protein. Smaller amounts of functional ATP7A have been reported as sufficient to cause milder phenotypes.[1] However, the association of spastic tetraparesis, ataxia, dystonia, and axonal motor neuropathy observed in our patient is remarkably different from any of the phenotypes reported with mutations in ATP7A. Wilson disease presents with heterogeneous hepatic and/or neurologic presentation, including variable combinations of dystonia, cerebellar, extrapyramidal, or psychiatric symptoms.[4] White matter lesions and cerebral atrophy are seen in mild Menkes disease, but T2-weighted high signal intensities, indicating abnormal copper deposition in the globus pallidus, are more characteristic for Wilson disease, a copper retention disorder caused by ATP7B mutations.[4] ATP7A variants as modifiers have been studied in Wilson disease based on a recent canine model carrying mutations in either ATP7A or ATP7B.[5] The 2 proteins share sequence homology for residues involved in copper translocation, regardless of their directionally different trafficking. A 38 amino acid segment within the third transmembrane domain is implicated in the trans-Golgi retention of ATP7A.[6] This same region is mutated in our patient suggesting subsequent ATP7A mislocalisation and misfolding in the disease mechanism. It is possible that the mutation triggers conformational changes and induces aberrant protein-protein interactions leading to impaired ATP7A trafficking.[3] Our case supports the large phenotypic variability of ATP7A mutations and highlights that deficiency of the two copper transporter ATPases may cause overlapping phenotypes. ATP7A seem to be a human disease gene with very variable clinical presentations, and better understanding of these phenotypes may point to mechanistic overlap with other copper metabolism disorders, e.g., aceruloplasminemia. We recommend genetic screening for ATP7A mutations in patients who manifest clinical symptoms of Wilson disease without mutations in ATP7B.
  6 in total

Review 1.  An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome.

Authors:  Zeynep Tümer
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

Review 2.  Small amounts of functional ATP7A protein permit mild phenotype.

Authors:  Lisbeth Birk Møller
Journal:  J Trace Elem Med Biol       Date:  2014-08-08       Impact factor: 3.849

3.  A genetic study of Wilson's disease in the United Kingdom.

Authors:  Alison J Coffey; Miranda Durkie; Stephen Hague; Kirsten McLay; Jennifer Emmerson; Christine Lo; Stefanie Klaffke; Christopher J Joyce; Anil Dhawan; Nedim Hadzic; Giorgina Mieli-Vergani; Richard Kirk; K Elizabeth Allen; David Nicholl; Siew Wong; William Griffiths; Sarah Smithson; Nicola Giffin; Ali Taha; Sally Connolly; Godfrey T Gillett; Stuart Tanner; Jim Bonham; Basil Sharrack; Aarno Palotie; Magnus Rattray; Ann Dalton; Oliver Bandmann
Journal:  Brain       Date:  2013-03-21       Impact factor: 13.501

4.  A Golgi localization signal identified in the Menkes recombinant protein.

Authors:  M J Francis; E E Jones; E R Levy; S Ponnambalam; J Chelly; A P Monaco
Journal:  Hum Mol Genet       Date:  1998-08       Impact factor: 6.150

5.  Role of the P-Type ATPases, ATP7A and ATP7B in brain copper homeostasis.

Authors:  Jonathon Telianidis; Ya Hui Hung; Stephanie Materia; Sharon La Fontaine
Journal:  Front Aging Neurosci       Date:  2013-08-23       Impact factor: 5.750

6.  The Menkes and Wilson disease genes counteract in copper toxicosis in Labrador retrievers: a new canine model for copper-metabolism disorders.

Authors:  Hille Fieten; Yadvinder Gill; Alan J Martin; Mafalda Concilli; Karen Dirksen; Frank G van Steenbeek; Bart Spee; Ted S G A M van den Ingh; Ellen C C P Martens; Paola Festa; Giancarlo Chesi; Bart van de Sluis; Roderick H J H Houwen; Adrian L Watson; Yurii S Aulchenko; Victoria L Hodgkinson; Sha Zhu; Michael J Petris; Roman S Polishchuk; Peter A J Leegwater; Jan Rothuizen
Journal:  Dis Model Mech       Date:  2016-01       Impact factor: 5.758

  6 in total
  5 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Movement disorders and neuropathies: overlaps and mimics in clinical practice.

Authors:  Francesco Gentile; Alessandro Bertini; Alberto Priori; Tommaso Bocci
Journal:  J Neurol       Date:  2022-06-03       Impact factor: 6.682

3.  Genetic heterogeneity of motor neuropathies.

Authors:  Boglarka Bansagi; Helen Griffin; Roger G Whittaker; Thalia Antoniadi; Teresinha Evangelista; James Miller; Mark Greenslade; Natalie Forester; Jennifer Duff; Anna Bradshaw; Stephanie Kleinle; Veronika Boczonadi; Hannah Steele; Venkateswaran Ramesh; Edit Franko; Angela Pyle; Hanns Lochmüller; Patrick F Chinnery; Rita Horvath
Journal:  Neurology       Date:  2017-03-01       Impact factor: 9.910

4.  Synthesis of a Novel Unexpected Cu(II)-Thiazolidine Complex-X-ray Structure, Hirshfeld Surface Analysis, and Biological Studies.

Authors:  Mezna Saleh Altowyan; Samar M S M Khalil; Dhuha Al-Wahaib; Assem Barakat; Saied M Soliman; Ali Eldissouky Ali; Hemmat A Elbadawy
Journal:  Molecules       Date:  2022-07-18       Impact factor: 4.927

Review 5.  Copper signalling: causes and consequences.

Authors:  Julianna Kardos; László Héja; Ágnes Simon; István Jablonkai; Richard Kovács; Katalin Jemnitz
Journal:  Cell Commun Signal       Date:  2018-10-22       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.